Zusammenfassung
Die zunehmende Kenntnis über physiologische und pathophysiologische Zusammenhänge bei sexuellen Störungen und die Entwicklung von somatischen Behandlungsverfahren tragen dazu bei, die bislang tabuisierte Thematik der sexuellen Entwicklung des alternden Mannes zu öffnen. Zu einer ganzheitlichen Sichtweise bedarf es neben der Berücksichtigung organischer und funktioneller Veränderungen auch der Beachtung psychosozialer Anforderungen und Anpassungsprozesse, die ein „erfolgreiches Altern“ auch in sexueller Hinsicht ermöglichen. Einflüsse auf sexuelle Aktivität und sexuelles Erleben werden anhand von repräsentativen Studien diskutiert (Partnerschaft, sexuelle Aktivität, subjektive Gesundheit, Persönlichkeitsmerkmale). Physiologische Veränderungen im sexuellen Reaktionszyklus schaffen eine Vulnerabilität für psychogene Einflüsse, u.a. Depressionen, Fehlvorstellungen, Versagensängste und Kommunikationsprobleme in der Partnerschaft. Die altersassoziierte Zunahme von Erektions- und Ejakulationsstörungen, die auch auf dem Hintergrund der zunehmenden Morbidität, Medikamenteneinnahme und Lebensstilveränderungen zu sehen ist, schließt eine befriedigend erlebte sexuelle Aktivität auch im hohen Alter nicht aus. Daher erscheint die Beratung des alternden Mannes im Hinblick auf den Umgang mit veränderten sexuellen Reaktionen, Lebensstil und anderen altersassoziierten Veränderungen ein wesentlicher Teil der gezielten Diagnostik und Therapie bei sexuellen Störungen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB (1998) The relationship between depressive Symptoms and male erectile dysfunction: Cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 60:458–465
Baltes P, Baltes M (1989) Erfolgreiches Altern: Mehr Jahre und mehr Leben. In: Baltes M, Kohli M, Sames K (Hrsg) Erfolgreiches Altern, Huber, S 5–18
Beutel M (1999) Psychosomatic aspects in the diagnosis and treatment of erectile dysfunction. Andrologia 31 (Suppl 1): 37–44
Beutel ME, Wiltink J (2000) Altersbeschwerden und Testosterondefizit aus psychosomatischer Sicht. Urologe A 39:414–417
Beutel ME, Kayser E, Kehde S, Dommer T, Bleichner F, Schlüter K, Baumann J (2000) Berufliche Belastungen, psychosomatische Beschwerden und Lebenszufriedenheit in der zweiten Hälfte des Berufslebens — Vergleich von 3 Altersgruppen in der psychosomatischen Rehabilitation. Psychotherapeut 45:72–81
Beutel M, Schumacher J, Weidner W, Brähler E (2002a) Sexual activity, sexual and partnership satisfaction in ageing men — results from a German representative Community study. Andrologia 34:22–28
Beutel ME, Weidner W, Schwarz R, Wiltink J, Brähler E (2002b) Complaints of the ageing male based on a representative Community study. Eur Urol 41:85–93
Blanker MH, Bohnen AM, Groeneveld FPMJ et al. (2001a) Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. JAGS 49:436–442
Blanker MH, Bosch LHR, Groeneveld FPMJ et al. (2001b) Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 57:763–768
Blanker MH, Driessen LFC, Bosch JLHR et al. (2002) Health Status and its correlate among Dutch community-dwelling older men with and without lower urogenital tract dysfunction. Eur Urol 41: 602–607
Brähler E, Unger U (1994) Sexuelle Aktivität im höheren Lebensalter im Kontext von Geschlecht, Familienstand und Persönlichkeitsaspekten Ergebnisse einer repräsentativen Befragung. Z Gerontologie 27:110–115
Brandenburg H, Sperling H, Hartmann U, Truß CM, and Stief C (2002) Sexualität im Alter. Urologe 41:346–349
Bretschneider JG, McCoy NL (1998) Sexual interest and behavior in healthy 80-to 102-year olds. Arch Sex Behav 17:109–129
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 151: 54–61
Gray A, Berlin JA, McKinlay JB et al. (1991) An examination of research design effects on the association of testosterone and male aging: results of a metaanalysis. J Clin Epidemiol 7:671–684
Heinemann LAJ, Thiel C, Assmann A, Zimmermann T, Hummel W, Vermeulen A (2000) Sex differences in “climacteric Symptoms” with increasing age? A hypothesis-generating analysis of crosssectional population surveys. Aging Male 3:124–131
Johannes C, Araujo AB, Feldman HA, Derby C, Kleinman KP, McKinlay JB (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 163:460–463
Lehr U (1996) Psychologie des Alterns. Quelle & Meyer, Wiesbaden
Lue TF (2000) Erectile dysfunction. N Engl J Med 342:1802–1813
Marandola P, Musitelli S, Noseda R et al. (2002) Love and sexuality in aging. Aging Male 5:103–113
Masumori N, Tsukamoto T, Kumamoto Y et al. (1999) Decline of sexual function with age in Japanese men compared with American men — results of two community-based studies. Urology 54: 335–344
Mulligan T, Retchin SM, Chincilli VM, Bettinger CB (1988) The role of aging and chronic disease in sexual dysfunction. JAGS 36: 520–524
Pfeiffer E, Davis GC (1972) Determinants of sexual behavior in middle and old age. JAGS 20:151–158
Radebold, H., (1992) Psychodynamik und Psychotherapie älterer. Springer, Berlin Heidelberg New York Tokio
Schiavi RC, Rehman J (1995) Sexuality and aging. Urol Clin North Am 22:711–726
Thiele A (1999) Körperliches Altern und psychisches Befinden. Theoretische überlegungen und empirische Ergebnisse aus einer Studie zum alternden Mann. Z Med Psychol 8:159–166
Vermeulen A (2000) Andropause. Maturitas 34:5–15
Weidner W, Altwein J, Hauck E, Beutel M, Brähler E (2001) Sexuality of the elderly. Urol Int 66:181–184
Werner AA (1939) The male climacteric. JAMA 126:472–477
Adams MA (2000) Endothelial dysfunction: the crux of vascular dysregulation in erectile dysfunction. Int J Impotence Res 12, 9th World Meeting on Impotence Research, Perth, p. 11: S 17
Alcorn JF, Toepfer JR, Leipheimer RE (1999) The effects of castration on relaxation of rat corpus cavemosum smooth muscle in vitro. J Urol 161:686–689
Anderson M, Nicholson B, Louie E et al. (1998) An analysis of vasculogenic erectile dysfunction as a potential predictor of occult cardiac disease. J Urol 159 (Suppl 30): p 30
Andersson KE, Holmquist F (1990) Mechanisms for contraction and relaxation of human penile smooth muscle. Int J Impotence Res 2:209–225
Andersson KE, Wagner G (1995) Physiology of penile erection. Physiol Rev 75:191–236
Andersson KE (1999) Classification, function and regulation of alpha adrenergic receptors in human penile tissue. Vortrag Pre-Congress Session of ESIR: Erectile Dysfunction. XIVth Congress of EAU, Stockholm, April 7,1999
Baba K, Yajima M, Carrier S et al (1994) Effect of testosterone on nitric oxide synthasecontaining nerve fibres and intracavernous pressure in rat corpus cavemosum. Int J Impotence Res 6, Suppl. 1, D6
Behre HM, Kliesch S, Meschede D, Nieschlag E (1994) Hypogonadismus und Infertilität des Mannes. In: Gerok W, Hartmann F, Pfreundschuh M (Hrsg) Klinik der Gegenwart. Urban & Schwarzenberg, München, S 1–73
Berges RR, Pientka L, Höfner K, Senge T, Jonas U (2001) Male lower urinary tract Symptoms and related health care seeking in Germany. Eur Urol 39:682–687
Beutel M (1999) Psychosomatic aspects in the diagnosis and treatment of erectile dysfunction. Andrologia 31 (Suppl): 37–44
Beutel M, Wiltink J, Schwarz R, Weidner W, Brähler E (2002) Complaints of the ageing male based on a representative Community study. Eur Urol 41:85–93
Bischoff E (2002) Enhanced penile erections through the soluble guanylyl cyclase stimulator BAY 41–2272 in conscious rabbits. Int J Impotence Res 14 (Suppl 4): S 41
Bischoff E, Niewohner U, Haning H et al. (2000) Vardenafil, a new PDE 5 inhibitor, increases cGMP in rabbit corpus cavemosum. Int J Impotence Res 12 (Suppl 3): S67, A24
Bischoff E, Mondritzki T, Niewoehner U et al. (2002) Vardenafil improved erections in rabbits longer than expected from half-life. Int J Impotence Res 14 (Suppl 4): S 42
Bivalacqua TJ, Champion HC, Mehta YS et al. (2000) Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impotence Res 12 (Suppl5): S8–S17
Bivalacqua T, Champion HC, Abdel-Mageed AB et al. (2001) Gene transfer of prepro-calcitonin gene related peptide restores erectile function in the aged rat. Int J Impotence Res 13 (Suppl. 4): S16
Blonde L, Korenman SG, Siegel RL et al. (2000) Sildenafil citrate for treatment of erectile dysfunction is similarly effective in men with type 1 and type 2 diabetes mellitus. Diabetes 49 (Suppl 1): A88
Boolell M, Allen MJ, Ballard SA et al. (1996) Sildenafil: an orally active type 5 cyclic GMP-specific Phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impotence Res 8: 47–52
Brock GB, McMahon CG, Chen KK et al. (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analysis. J Urol 168:1332–1336
Buvat J, Lemaire A (1997) Endocrine Screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 158:1764–1767
Buvat J, Costa P, Morlier D et al. (1998) Double-blind multicenter study comparing Alprostadil alpha cyclodextrin with Moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol 159:116–119
Casabe A, Cobreros C, Bechara A et al. (2001) Drop out reason in responders to Sildenafil. Int J Impotence Res 13 (Suppl 2): S5
Chavan A (1997) Penisangiographie bei erektiler Dysfunktion. In: Stief CG, Hartmann U, Höfner K, Jonas U (Hrsg) Erektile Dysfunktion. Springer, Berlin Heidelberg New York Tokio, S 177–185
Chen J, Mabjeesh N, Greenstein A et al. (2001) Clinical efficacy of Sildenafil in patients on chronic dialysis. J Urol 819–821
Chiou RK, Pomeroy BD, Chen WS, Anderson JC, Wobig RK, Taylor R (1998) Hemodynamic patterns of pharmacologically induced erection: evaluation by color doppler sonography. J Urol 159: 109–112
Christ GJ, Smith WL, Santizo C (1999) Gene therapy with K+ Channels preserves erectile capacity in the face of diminished neuronal innervation following 12-16 weeks of experimental diabetes in rats. J Urol 161/4 (Suppl): 210
Conti CR, Pepine CR, Sweeney M (1999) Efficacy and safety of Sildenafil citrate in treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 83 (Suppl 5A): 29C–34C
Corbin JD, Francis SH, Webb D (2002) Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60, Suppl. SB: 4–11
Corbin JD, Francis SH (2002) Pharmacology of Phosphodiesterase 5 inhibitors. IJCP 56 (6): 453–459
Dula E, Bukofzer S, Perdok R et al. (2001) Double-blind, cross-over comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 39: 558–564
Ernst E, Pittler MH (1998) Yohimbin for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol 159,433–436
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the massachusetts male aging study. J Urol 151:54–61
Fowler C, Miller J, Sharief M and the Sildenafil Study Group (1999) Viagra (Sildenafil Citrate) for the treatment of erectile dysfunction in men with multiple sclerosis. Ann Neurol 46:497
Garban H, Marquez D, Magee T et al. (1997) Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod 56:954–963
Giraldi A, Sereis S, Autieri M et al. (1996) Endothelin-1 as a putative modulator of gene expression and cellular physiology in human corporal smooth muscle. Int J Impotence Res 8:100
Giuliano F, Bernabe J, Brown K et al. (1997) Medical preoptic area elicits penile erection through activations of sympathetic and parasympathetic outflows in the rat. J Urol 157, Suppl No. 4:415
Giuliano F, Longueville F, Tang Y et al. (1997) Evidence for Oxytocin regulation of penile erection of the spinal cord level in the rat. J Urol 157, Suppl No. 4:359
Giuliano F, Hultling C, Elmasry WS et al. (1999) Randomized trial of Sildenafil for the t treatment of erectile dysfunction in spinal cord injury. Ann Neurol 46:15–21
Goldstein I, Lue TF, Padma-Nathan H et al. for the Sildenafil Study Group (1998) Oral Sildenafil in the treatment of erectile dysfunction. N Engl J Med 338:1397–1404
Goldstein I, Young JM, Fischer J et al. (2003) Vardenafil, a new Phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. Diabetes Care 26:1–7
Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z (1997) Does severity of ischemic coronary disease correlete with erectile dysfunction? Int J Impotence 9:123–126
Hagemann JH, Stief CG (1997) Doppler-, Duplex-und farbkodierte Duplexuntersuchung der penilen Gefäße. In: Stief CG, Hartmann U, Höfner K, Jonas U (Hrsg) Erektile Dysfunktion. Springer, Berlin Heidelberg New York Tokio, S 141–159
Hauck EW, Schroeder-Printzen I, Weidner W (1998) Rationelle Diagnostik der erektilen Dysfunktion. Urologe A 37:495–502
Hauck EW, Heitz M, Schreiter F, Weidner W (1999) Induratio penis plastica. Akt Urol 30:386–404
Hauck EW, Schroeder-Printzen I, Weidner W (2001) Gibt es heute noch eine Indikation zur Kavernosographie und-metrie? Urologe B 41: 132–134
Hauri D (2003) Erectile dysfunction in the elderly man. Urol Int 70: 89–99
Hellstrom W, Overstreet J, Shen C et al. (2002) Tadalafil has no clinical relevant effect on semen. Int J Impotence Res 14 (Suppl 4): S62
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kluseman KP, McKinley JB (2000) Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massuchetts Male Aging Study. J Urol 2000:460–463
Kifor J, Williams G, Vickers MA et al. (1997) Tissue Angiotensin II as a modulator of erectile function. J Urol 157:1920–1925
Kirkeby HJ (1994) Regulation of penile venous outflow. Experimental studies on endogenous control mechanisms. Int J Impotence Res 6 (Suppl 2): 1–36
Kloner RA, Brown M, Prisant LM et al. (2001) Effect of Sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 14:70–73
Lawrence JSS, Madakasira S (1992) Evaluation and treatment of premature ejaculation: a critical review. Int J Psychiatry Med 22: 77–97
Lerner SE, Melman A, Christ GJ (1993) A review of erectile dysfunction: new insights and more questions. J Urol 149:1246–1255
Lindia J, Nargund R, Sebhat J et al. (2001) Erectogenic effects of a selective melanocortin-4 receptor (MC 4-R) agonist in a rat model of erectile activity. Int J Impotence Res 13 (Suppl 5): S55
Liu SP, Guh JH, Teng CM et al. (2000) YC-1 relaxes rabbit cavernous smooth muscle via soluble guanylate cyclase Stimulation. Int J Impotence Res. 12, 9th World Meeting on Impotence Research, Perth, p. 65 Abstr. M 96
Maytom MC, Derry FA, Dinsmore WW et al. (1999) A two-part pilot study of Sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord 37:110–116
Mazur A, Mueller U, Krause W, Booth A (2002) Causes of sexual decline in aging married men: Germany and America. Int J Impotence Res 14:101–106
McMahon CG, Samali R, Johnson H (1999) Treatment of intracorporeal injection non-response with Sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 162: 1992–1998
McVary KT, Pollepalle S, Riggi S et al. (1998) Topical SEPA/PGE1-gel for the treatment of erectile dysfunction. J Urol 159/5 (Suppl): 239
Mills TM, Chitaley K, Lewis RW (2001) Vasoconstriction in erectile physiology. Int J Impotence Res 13 (Suppl 5): S29–S34
Mills TK, Chitaley R, Lewis RW et al. (2002) Topical application of Rho kinase inhibitor — will it cause erection? Int J Impotence Res 14 (Suppl 3): S5
Moiderings GJ, Goethert M, van Ahlen H et al. (1989) Noradrenalin release in human corpus cavemosum and its modulation via presynaptic alpha2 adrenoceptors. Fundam Clin Pharmacol 3: 497–504
Montague DK, Lakin MM (1992) False diagnoses of venous leak impotence. J Urol 148:148–149
Morales A, Lunenfeld B (2001) Standards, guidelines and recommendations of the International Society for the Study of the Aging male (ISSAM). Androgen replacement therapy in aging men with secondary hypogonadism. The Aging male 4:151–162
Morales A and the Canadian MUSE-Investigators (1998) Clinical assessment of the efficacy and safety of MUSE (Alprostadil) in subjects with erectile dysfunction. Int J Impotence Res 10 (Suppl 3)
Morales A, Heaton JPW, Carson III CC (2000) Andropause: a misnomer for a true clinical entity. J Urol 163:705–712
Morley JE, Korenmann SG, Kaiser FE, Mooradian AD, Viosca S (1988) Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older men. Am J Med 84:445–448
Mulhall JP, Abdel-Moneim A, Abobakr R, Goldstein I (2001) Improving the accuracy of vascular testing in impotent men: correcting hemodynamic alterations using a vasoactive medication re-dosing schedule. J Urol 166:923–926
Nakane MG, Hsieh G, Miller LN et al. (2002) Activation of soluble guanylate cyclase causes relaxation of corpus cavemosum tissue: synergism of nitric oxide and YC-1. Int J Impotence Res 14:121–127
NIH (1993) NIH Consensus development panel: Impotence. JAMA 270:83–90
O’Leary MP (2001): Quality of life and sexuality: methological aspects. Eur Urol 40 (Suppl 3): 13–18
Olsson AM, Persson CA (2000) Efficacy and safety of Viagra (Sildenafil citrate) in men with cardiovascular disease and erectile dysfunction. Urologe A 39 (Suppl 1): S118
Padma-Nathan H, Agre K, Fromm S et al. (2000) Efficacy of apomorphine SL vs. Placebo for erectile dysfunction in patients with hypertension. 9th World Meeting on Impotence Research, Perth. Int J Impotence Res 12
Patterson B, Bedding A, Jewell H et al. (2001) The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of Tadalafil (IC351). Int J Impotence Res 13 (Suppl 4): S43
Porst H (1996) Review article. The rationale for Prostaglandin E1 in erectile failure: A survey of world-wide experience. J Urol 155: 802–815
Porst H (1997) Transurethral Alprostadil with MUSE (Medicated Urethral System for Erection) vs. intracavernous Alprostadil — a comparative study in 103 patients with erectile dysfunction. Int J Impotence Res 9:187–192
Porst H (2000) Manual der Impotenz. Uni-Med, Bremen
Porst H, Buvat J, Meuleman E et al. (1998) Intracavernous Alprostadil Alfadex — an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impotence Res 10:225–231
Porst H, Rosen R, Padma-Nathan H et al. (2001) The efficacy and tolerability of vardenafil, a new, oral, selective Phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impotence Res 13:192–199
Porst H, Padma-Nathan H, Giuliano F et al. (2003) Efficacy of Tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial. Urology 62:121–125
Pritzker MR (1999) The penile stress test: a window to the hearts of man? Circulation 100:1–711
Rendell MS, Rajfer J, Wicker PA et al. (1999) Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 281:421–426
Rosen R, Scidman S, Menza M et al. (1999) The efficacy and safety of Viagra (Sildenafil citrate) for the treatment of erectile dysfunction in men with comorbid depression. Poster. First International Consultation on Erectile Dysfunction, Paris, July 1–3
Rosen RC, Cappelleri JC, Gendrano III N (2002a) International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impotence Res 14:226–244
Rosen R, Leary M, Altwein J et al. (2002b) LUTS and male sexuality: findings from the multi-national survey of the aging male (MSAM-7). Int J Impotence Res 14 (Suppl 3): S25
Saenz de Tejada I (1995) Commentary on mechanisms for the regulation of penile smooth muscle contractility. J Urol 153:1762
Saenz de Tejada I, Angulo J, Cuevas P et al. (2001) The Phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE 5 inhibitor vardenafil. Int J Impotence Res. 13:282–290
Sandhu D, Curless E, Dean J et al. (1999) A double blind, placebo-controlled study of intracavernosal vasoactive intestinal Polypeptide and phentolamine mesylate in a novel autoinjectorfor the treatment of non-psychogenic erectile dysfunction. Int J Impotence Res 11:91–97
Schmid DM, Schurch B, Hauri D (2001) Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients. Eur Urol 38:184–193
Shakir SAW, Wilton L, Boshier A et al. (2001) Cardiovascular events in users of silldenafil: results from the first phase of prescription event monitoring in England. BMJ 322:651–652
Slob AK, Cornelissen S, Dohle GR, Gijs L, van der Werfften Bosch JJ (2002) The limited practical value of color Doppler sonography in the differential diagnosis of men with erectile dysfunction. Int J Impotence Res 14:201–203
Souverein PC, Egberts AC, Meuleman EJ et al. (2002) Incidence and determinants of Sildenafil (dys)continuation: the Dutch cohort of Sildenafil users. Int J Impotence Res 14:259–265
Sperling H, Rübben H (2002) Erektile Dysfunktion (ED) — Impotenz. In: Jacobi GH (Hrsg) Praxis der Männergsundheit. Thieme, Stuttgart, S 204–211
Stief CG, Hartmann U (1997) Praktisches Vorgehen und kritische Bewertung. In: Stief CG, Hartmann U, Höfner K, Jonas U (Hrsg) Erektile Dysfunktion. Springer, Springer, Berlin Heidelberg New York Tokio, S 96–105
Stief CG, Kellner B, Härtung C et al. (1997) Computer-assisted evaluation of the smooth-muscle of the corpora cavernosa by fast fourier transformation. Eur Urol 31:329–334
Stief C, Jünemann KP, Bühmann W etal. (2001) Leitlinie zur Diagnostik und Therapie von Libido-und Erektionsstörungen. Urologe A 40:331–339
Vermeulen A, Kaufman JM, Giagulli VA (1999) Influence of some biological indices on sex hormone binding globulin and androgen levels in the aging and obese male. J Clin Endocrinol Metab 81: 1821–1827
Wagner G, Maytom M, Smith MD et al. (1999) Analysis of the efficacy of Sildenafil (Viagra) in the treatment of male erectile dysfunction in elderly patients. Poster. First International Consultation on Erectile Dysfunction, Paris, July 1–3
Weidner W, Schroeder-Printzen I, Weiske WH, Vosshendrich R (1997) Sexual dysfunction in Peyronie’s disease: an analysis of 222 patients without previous local plaque therapy. J Urol 157:324–328
Wespes E, Amar E, Hatzichristou D, Montorsi F, Pryor J, Vardi Y (2002) Guidelines an erectile dysfunction. Eur Urol 41:1–5
Wessels H, Levine N, Hardley ME et al. (2000) Melanocortin receptor agonists, penile erection and sexual motivation: human studies with Melanotan II. Int J Impotence Res 12 (Suppl 4): S74–S79
Wiltink J, Hauck EW, Phädayanon M, Weidner W, Beutel ME (2003, in press) Validation of the German version of the International Index of Erectile Function (IIEF) in patients with erectile dysfunction, Peyronie’s disease and controls. Int J Impotence Res
Bondarenko VO (2000) The significance of the androgen-estrogen ratios in the clinical picture of sexual disorders in men (Ukranian). Lik-Sprava 1:44–47
Buddeberg C (1987) Sexualberatung, 2. Aufl. Enke, Stuttgart
Burger B, Weidner W, Altwein JE (1999) Prostate and Sexuality: an Overview. Eur Urol 35:177–184
Calais Da Silva F, Marquis P, Deschaseaux P et al. (1997) Relative importance of sexuality and quality of life in patients with prostatic Symptoms. Results of an International Study. Eur Urol 31: 272–280
Fath R (2002) Prostatahyperplasie beeinträchtigt das Sexualleben. Pharmareport, Beilage. Urologe B 42
Höfner K, Claes H, De Reijke TM et al. (1999) Tamsulosin 0,4 mg once daily: effect on sexual function in patients with lower urinary tract Symptoms suggestive of benign prostatic obstruction. Eur Urol 36:335–341
Krause W, Weidner W (1998) Andrologie — Krankheiten der männlichen Geschlechtsorgane, 3. Aufl. Enke, Stuttgart 1998
Lepor H et al. (1998) Phase III multicenter placebo — controlled study of Tamsulosin in benign prostatic hyperplasia. Urology 51: 892–900
Marberger MJ (1998) Long-term effects of finasteride in patients with benign prostatic hyperplasia. A double blind, placebo-controlled, multicenter study. Urology 51:677–686
McConnell JD, Braskewitz R, Walsh P et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338:557–563
Porst H (2000) Manual der Impotenz. Uni-Med, Bremen
Puente JG, Sweeney M, Cary MM et al. (1998) Relationship between age, lower urinary tract Symptoms (LUTS) and various domains of erectile dysfunction (ED) in 1098 patients with BPH in the predict study. J Urol 159 (Suppl 5): 331 (Abstr 1272)
Roehrborn C et al. (2001) Efficacy and safety of once daily alfuzosin in the treatment of lower urinary tract Symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 58:953–959
Zlotta AR, Schulman CC (1999) BPH and sexuality. Eur Urol 36 (Suppl 1): 107–112
Albert CM, Mittleman MA, Chae CU (2000) Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med 343:1355–1361
Anderson KM, Wilson PW, Odell PM, Kannel WB (1991) An updated coronary risk profile. A Statement for health Professionals. Circulation 83:356–362
Anderson KM, Odell PM, Wilson PW, Kannel WB (1993) Cardiovascular disease risk profiles. Am Heart J 121:293–298
Azarbal B, Mirocha J, Shah P, Cercek B, Kaul S (2000) Adverse cardiovascular events associated with the use of Viagra. J Am Coli Cardiol 35:553A
Bayes de Luna A, Brugada P, Aguilar JC, Navarro-Lopez F (1991) Sudden cardiac death. Kluwer Academic, Dordrecht
Berner MM (2002) Sexualität bei kardialen Erkrankungen. DMW 127: 279–283
Bohlen JG, Held JP, Sanderson MO, Patterson RP (1984) Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch Intern Med 144:1745–1748
Cantwell JD (1981) Sex and the heart. Med Aspects Hum Sex 15: 14–23
Cheitlin MD, Hutter AM Jr, Brindis RG et al. (1999) ACC/AHA expert consensus document. Use of Sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology / American Heart Association. J Am Coli Cardiol 33:273–282
De Busk R, Drory Y, Goldstein I et al. (2000) Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 86:175–181
Drory Y, Shapira I, Fisman EZ, Pines A (1995) Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 75:835–837
Drory Y, Fisman EZ, Shapira Y, Pines A (1996) Ventricular arrhythmias during sexual activity in patients with coronary artery disease. Chest 109:922–924
Ebrahim S, May M, Ben Shlomo Y et al. (2002) Sexual intercourse and risk of ischaemic stroke and coronary heart disease: the Caerphilly study. J Epidemiol Community Health 56:99–102
Falk RH (2001) The cardiovascular response to sexual activity: do we know enough? Clin Cardiol 24:271–275
Garcia-Barretto D, Sin-Chesa C, Rivas-Estany E (1986) Sexual intercourse in patients who have had a myocardial infarction. J Cardiopulm Rehabil 6:324–328
Hellerstein HK, Friedman EH (1970) Sexual activity and the postcoronary patient. Arch Intern Med 125:987–999
Jimbo H, Doi H, Matsumoto K (2000) Cerebrovascular diseases caused by sexual intercourse. 4th World Stroke Conference, Melbourne 2000
Johnston BL, Fletcher GF (1979) Dynamic electrocardiographic recording during sexual activity in recent post-myocardial infarction and revascularization patients. Am Heart J 98:736–741
Kannel WB, Thomas HE (1982) Sudden coronary death: The Framingham Study. Ann NY Acad Sci 328:3–21
Kavanagh T, Shephard RJ (1977) Sexual activity after myocardial infarction. Can Med Assoc J 116:1250–1253
Lifschultz BD, Donoghue ER (1983) Air embolism during intercourse in pregnancy. J Forensic Sci 28:1021–1022
Mann S, Craig MWM, Gould B, Raftery EB (1980) Coital blood pressure in hypertensives. Circulation 62 (Suppl 3): 111–137
Master WH, Johnson VE (1966) Human sexual response. Little, Brown & Co., Boston
Moller J, Ahlbom A, Hulting J et al. (2001) Sexual activity as a trigger of myocardial infarction. A case-crossover analysis in the Stockholm Heart Epidemiology Programme (SHEEP). Heart 86:387–390
Moss AJ, Benhorin J (1990) Prognosis and management after a first myocardial infarction. N Engl J Med 322:743–753
Muller JE, Mittleman MA, Maclure M, Sherwood JB, Tofler GH (1996) Triggering myocardial infarction by sexual activity. JAMA 275: 1405–1409
Nemec ED, Mansfield L, Kennedy JW (1976) Heart rate and blood pressure responses during sexual activity in normal males. Am Heart J 92:274–277
Paolillo V, Marra S, Spadaccini F, Angelino PF (1980) Dynamic electrocardiographic recording during sexual activity in recent post-myocardial infarction and revascularization patients. Am Heart J 100:763
Parzeller M, Raschka C, Bratzke H (1999) [Sudden cardiovascular death during sexual intercourse — results of a legal medicine autopsy study]. Z Kardiol 88:44–48
Parzeller M, Raschka C, Bratzke H (2001) Sudden cardiovascular death in correlation with sexual activity — results of a medicolegal postmortem study from 1972–1998. Eur Heart J 22:610–611
Stein RA (1977) The effect of exercise training on heart rate during coitus in the post myocardial infarction patient. Circulation 55: 738–740
Ueno M (1963) The so-called coition death. Jpn J Leg Med 127: 333–340
Wenger NL, Hellerstein HK, Haskeil WL (1978) Rehabilitation of the coronary patient. In: Design and implementation of cardiac conditioning program. Churchill Livingstone, Edinburgh, p 147
Rights and permissions
Copyright information
© 2004 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Beutel, M.E. et al. (2004). Sexualität. In: Männersprechstunde. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18705-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-18705-6_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-00915-3
Online ISBN: 978-3-642-18705-6
eBook Packages: Springer Book Archive